EDCTP side event at UNGA79 Science Summit

26 Sep 2024 17:00 CEST - 26 Sep 2024 19:00 CEST
Virtual
Type of event EDCTP meeting

Investing in clinical research in Africa to develop local solutions against the global challenge of Antimicrobial Resistance (AMR)

26 September 2024 11:00-13:00 EDT | 17:00-19:00 CET (Virtual)

As part of the Science Summit during the 79th United Nations General Assembly (SSUNGA79), EDCTP will organise a side event that aims to illustrate the value of investing in clinical research and development of accessible and affordable antibiotics, diagnostics, and vaccines for addressing unmet medical needs in Africa through a global partnership such as EDCTP.

The objectives of the session will be to:

  • Promote awareness about EDCTP and its role and contribution towards attaining the SDGs
  • Highlight the role of R&D in tackling AMR and showcase practical examples of how the EDCTP programmes have supported clinical research on AMR
  • Discuss the priority elements for mitigating AMR and achieving the SDGs, including adopting a One Heath approach, ensuring equitable access to antimicrobials, recognising prevention as the cornerstone of response, and safeguarding adequate, sustainable and predictable financing for antibiotic, diagnostics, and vaccine development.

This side session will take place virtually.

Visit the SSUNGA79 website to access the agenda of the event.

Registration is free. After registration, please ensure to add the virtual session to your schedule.

Agenda

 

Co-Chairs:

  • Marcel Tanner, EDCTP High Representative, Switzerland
  • Marleen Temmerman, Director Women’s Health, Faculty of Heath Sciences, Aga Khan University, Kenya

 

17:00-17:05
Welcome and introduction from the co-Chairs

17:05-17:15
Combatting the global AMR pandemic and implementing the health SDGs through an African-European global health partnership for clinical research and development
Michael Makanga, Executive Director; Global Health EDCTP3 Joint Undertaking, Belgium

17:15-17:25
Case study 1 – Isoniazid resistance: Resetting the score with boosted ethionamide (BeTo-TB)
David Barros, Vice President and Head of Global Health Medicines R&D Pharma Research Unit, GlaxoSmithKline GSK, Spain

17:25-17:35
Case study 2 – Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- and second-line antiretroviral therapy in Cameroon: The READY-Study
Joseph Fokam, Head of Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Cameroon

17:35-17:45
Case Study 3 – The Pan-African Network for Rapid Research, Response, Relief and Preparedness for Infectious Disease Epidemics (PANDORA-ID-NET) and the One Health approach
Francine Ntoumi, Founder, President and Executive Director of the Congolese Foundation for Medical Research (FCRM), Congo

17:45-17:55
Case Study 4 – Severe neonatal infection adaptive platform trials in Africa (SNIP-AFRICA)
Julia Bielicki, Penta Foundation Board member and Reader at City St George’s, University of London, United Kingdom

17:55-18:10
Audience Q&A

18:10-18:35
Panel discussion on priority investment areas for mitigating AMR and the role that Global Health EDCTP3 and its partners can play in implementing mechanisms for addressing UN priorities and helping to set the future agenda

  • Irene Norstedt, Director, Directorate People: Health & Society, Directorate-General for Research and Innovation, European Commission
  • Samuel Kariuki, Director – Eastern Africa, Drugs for Neglected Diseases initiative (DNDi), Kenya
  • Yewande Alimi, AMR and One Health Unit Lead, Africa Centres for Disease Control and Prevention (Africa CDC), Ethiopia
  • Jutta Rheinhard-Rupp, Head of the Global Health Institute, Merck KGaA, Germany

 

18:35-18:55
Audience Q&A and discussion

18:55-19:00
Closing remarks from the co-Chairs